These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Recruiting minorities into clinical trials: toward a participant-friendly system. Swanson GM; Ward AJ J Natl Cancer Inst; 1995 Dec; 87(23):1747-59. PubMed ID: 7473831 [TBL] [Abstract][Full Text] [Related]
43. Involving South Asian patients in clinical trials. Hussain-Gambles M; Leese B; Atkin K; Brown J; Mason S; Tovey P Health Technol Assess; 2004 Oct; 8(42):iii, 1-109. PubMed ID: 15488164 [TBL] [Abstract][Full Text] [Related]
44. Ethical issues of intervention trials in cancer. Sancho-Garnier H; Joseph R IARC Sci Publ; 1996; (136):121-2. PubMed ID: 8791122 [No Abstract] [Full Text] [Related]
45. Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges. Lü J; Zhang J; Jiang C; Deng Y; Özten N; Bosland MC Nutr Cancer; 2016; 68(1):1-17. PubMed ID: 26595411 [TBL] [Abstract][Full Text] [Related]
46. Cancer chemoprevention: factors influencing attitudes towards chemopreventive agents in high-risk populations. Iwuji C; Howells L; Thomasset S; Brown K; Steward W; Barwell J; Thomas A Eur J Cancer Prev; 2014 Nov; 23(6):594-601. PubMed ID: 25259886 [TBL] [Abstract][Full Text] [Related]
48. Applying a Conceptual Framework to Maximize the Participation of Diverse Populations in Cancer Clinical Trials. Napoles A; Cook E; Ginossar T; Knight KD; Ford ME Adv Cancer Res; 2017; 133():77-94. PubMed ID: 28052822 [TBL] [Abstract][Full Text] [Related]
49. Criteria for implementation of large and multiagent clinical chemoprevention trials. Meyskens FL J Cell Biochem Suppl; 2000; 34():115-20. PubMed ID: 10762023 [TBL] [Abstract][Full Text] [Related]
50. Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future. Omenn GS Eur J Cancer Prev; 2007 Jun; 16(3):184-91. PubMed ID: 17415088 [TBL] [Abstract][Full Text] [Related]
52. Feasibility of a telephone survey to recruit health maintenance organization members into a tamoxifen chemoprevention trial. Daly M; Seay J; Balshem A; Lerman C; Engstrom P Cancer Epidemiol Biomarkers Prev; 1992; 1(5):413-6. PubMed ID: 1305474 [TBL] [Abstract][Full Text] [Related]
53. Second international cancer chemoprevention conference. Benner SE; Pastorino U; Lippman SM; Hong WK Cancer Res; 1994 Feb; 54(3):854-6. PubMed ID: 7905788 [No Abstract] [Full Text] [Related]
54. Cancer chemoprevention. Greenwald P BMJ; 2002 Mar; 324(7339):714-8. PubMed ID: 11909790 [No Abstract] [Full Text] [Related]
55. Statistical considerations of chemoprevention clinical trials in prostate cancer. Sylvester R; Collette L Eur Urol; 1999; 35(5-6):519-22. PubMed ID: 10325518 [TBL] [Abstract][Full Text] [Related]
56. New opportunities in chemoprevention research. Kucuk O Cancer Invest; 2002; 20(2):237-45. PubMed ID: 11901544 [TBL] [Abstract][Full Text] [Related]
59. Current strategies of cancer chemoprevention: 13th Sapporo cancer seminar. Boone CW; Wattenberg LW Cancer Res; 1994 Jun; 54(12):3315-8. PubMed ID: 7911397 [No Abstract] [Full Text] [Related]
60. Criteria of evidence to move potential chemopreventive agents into late phase clinical trials. Kelly RJ; Lopez-Chavez A; Szabo E Curr Drug Targets; 2011 Dec; 12(13):1983-8. PubMed ID: 21158704 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]